References
- Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, et al. 2002. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 100(7):2367–2373. doi:https://doi.org/10.1182/blood-2002-01-0172.
- Arico M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, Martinetti, M, and Rusca, M, 1996. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 10:197–203.
- Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. 2011. How I treat hemophagocytic lymphohistiocytosis. Blood. 118(15):4041–4052. doi:https://doi.org/10.1182/blood-2011-03-278127.
- Yildiz H, Van Den Neste E, Defour JP, Danse E, Yombi JC Adult haemophagocytic lymphohistiocytosis: a Review. QJM 2020.
- Otrock ZK, Eby CS. 2015. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 90(3):220–224. doi:https://doi.org/10.1002/ajh.23911.
- Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, et al. 2016. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer. 122(18):2857–2866. doi:https://doi.org/10.1002/cncr.30084.
- Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, et al. 2017. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 123(17):3229–3240. doi:https://doi.org/10.1002/cncr.30826.
- La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, et al. 2019. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 133(23):2465–2477. doi:https://doi.org/10.1182/blood.2018894618.
- Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, et al. 2007. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48(2):124–131. doi:https://doi.org/10.1002/pbc.21039.
- Song Y, Wang Y, Wang Z. 2019. Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol. 186(5):717–723. doi:https://doi.org/10.1111/bjh.15988.
- Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S. 2001. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 19(10):2665–2673. doi:https://doi.org/10.1200/JCO.2001.19.10.2665.
- Schram AM, Berliner N. 2015. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 125(19):2908–2914. doi:https://doi.org/10.1182/blood-2015-01-551622.
- Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, et al. 2018. A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol. 183(1):68–75. doi:https://doi.org/10.1111/bjh.15506.
- Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M, et al. 2010. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 116(18):3418–3425. doi:https://doi.org/10.1182/blood-2010-02-270785.
- Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, Bernig T, Beutel K, Bode SFN, Kentouche K, et al. 2015. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 170(4):539–549. doi:https://doi.org/10.1111/bjh.13462.
- Collaborative study to evaluate the proposed 1st WHO International.
- Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen, JL, Wei, N, and Wang, Z, 2015. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 126:2186–2192. doi:https://doi.org/10.1182/blood-2015-05-644914.
- Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, et al. 2013. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 60(1):101–109. doi:https://doi.org/10.1002/pbc.24188.
- World Health Organisation. The WHO toxicity grading scale for determining the severity of adverse events. 2003. [Accessed 2015 Mar 22]. Available from URL: http://wwwicsscorg/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%20finalpdf.
- Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. 2011. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 52(4):613–619. doi:https://doi.org/10.3109/10428194.2010.551153.
- Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. 2014. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clinic Proceedings. 89(4):484–492. doi:https://doi.org/10.1016/j.mayocp.2013.12.012.
- Arca M, Fardet L, Galicier L, Riviere S, Marzac C, Aumont C, Lambotte, O, and Coppo, P, 2015. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 168(1):63–68. doi:https://doi.org/10.1111/bjh.13102.
- Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. 2014. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. The Journal of Immunology. 192(1):84–91. doi:https://doi.org/10.4049/jimmunol.1302282.
- Pommier Y, Leo E, Zhang H, Marchand C. 2010. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 17(5):421–433. doi:https://doi.org/10.1016/j.chembiol.2010.04.012.
- Ellin F, Landstrom J, Jerkeman M, Relander T. 2014. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 124(10):1570–1577. doi:https://doi.org/10.1182/blood-2014-04-573089.
- Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, et al. 2019. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 33(4):1047–1051. doi:https://doi.org/10.1038/s41375-018-0320-9.
- Mizrahi M, Ben-Chetrit E. 2009. Relapsing macrophage activating syndrome in a 15-year-old girl with Still’s disease: a case report. J Med Case Rep. 3(1):138. doi:https://doi.org/10.1186/1752-1947-3-138.
- Fei Q, Tian XK, Wu J, Zhu HM, Wang Y, Peng FY, Zhang, WJ, Yin, L, and He, X. 2018. Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis. Onco Targets Ther. 11:997–1004. doi:https://doi.org/10.2147/OTT.S153942.
- Castillo JJ Beltran BE Miranda RN Young KH Chavez JC Sotomayor EM 2016 EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management Am J Hematol 91(5)529–537 doi:https://doi.org/10.1002/ajh.24370
- Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, et al. 2014. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 165(6):786–792. doi:https://doi.org/10.1111/bjh.12823.
- Yildiz H, Bailly S, Van Den Neste E, Yombi JC. 2021. Clinical management of relapsed/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag. 17:293–304. doi:https://doi.org/10.2147/TCRM.S195538.
- Wang J, Zhang R, Wu X, Li F, Yang H, Liu L, Guo H, Zhang X, Mai H, Li H, et al. 2021. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 193(4):761–768. doi:https://doi.org/10.1111/bjh.17331.
- Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, and Wang, Z. 2019. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica 105(5): e210–e212. doi:https://doi.org/10.3324/haematol.2019.222471. .
- Liu P, Pan X, Chen C, Niu T, Shuai X, Wang J, Chen X, Liu J, Guo Y, Xie L, et al. 2020. Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adults. Blood. 135(11):826–833. doi:https://doi.org/10.1182/blood.2019003886.